Finnish start-up MVision AI has secured €5.4m ($5.85m) in post-seed financing to speed up radiotherapy treatment planning for cancer patients using artificial intelligence. The company’s technology uses AI-powered automatic segmentation tooling to create 3D models of organs and tumours for radio oncologists, rather than the manual processes that can take more than two weeks. MVision’s system shortens the process to minutes and has a CE mark and FDA clearance for radiotherapy planning. The platform aims to standardise cancer care and improve decision-making through cloud-based support tools for clinicians. The firm will use the financing to research new radiotherapy planning solutions and develop a cloud-based platform for cancer treatment.